Sun T, Mai S, Mao H, Li H, Duan Y, Meng S, Bao J, Ding N, Zong C Conjugate of structurally reassigned pneumococcal serotype 31 polysaccharide with CRM197 elicited potent immune response Carbohydrate Polymers289 (2022)
119414
The structure was elucidated in this paper NCBI PubMed ID:35483835 Publication DOI:10.1016/j.carbpol.2022.119414 Journal NLM ID:8307156 Publisher: Elsevier Correspondence: C. Zong <chengli.zonghainanu.edu.cn> Institutions: School of Pharmaceutical Sciences, College of Marine Science, Hainan University, Haikou 570228, China, The University of Sydney, NSW 2006, Australia, School of Pharmacy, Fudan University, Shanghai 201203, China
Around 100 Streptococcus pneumonia (Spn) serotypes have been discovered, 90% of the severe diseases in children are caused by 13 serotypes. With the success of pneumococcal bacterial polysaccharide conjugate vaccines (PCVs), the burden of pneumococcal disease has been significantly reduced. Serotype 31 is a non-vaccine serotype and has increased in prevalence. By using Nuclear Magnetic Resonance (NMR) as the primary tool, we report the revised serotype 31 polysaccharide (s-31-ps) structure as [→3)-β-D-Galf-(5/6-OAc)-(1→3)-β-D-Galp-(1→3)-β-L-Rhap-(2-OAc)-(1→2)-α-L-Rhap-(1→4)-β-D-GlcpA-(1→]n. Furthermore, the reductive amination-conjugate of serotype 31 polysaccharide and cross reacting material (CRM197) protein was prepared in organic solvent (N,N-dimethylformamide, DMF) instead of water. The reaction is faster, and the DMF conjugate elicited comparable immune responses with the aqueous conjugate. S-31-ps conjugate vaccine has the potential of being included in the next-generation PCV vaccines.
Sun T, Mai S, Mao H, Li H, Duan Y, Meng S, Bao J, Ding N, Zong C Conjugate of structurally reassigned pneumococcal serotype 31 polysaccharide with CRM197 elicited potent immune response Carbohydrate Polymers289 (2022)
119414
/Variants 0/-+
|
-3)-b-D-Galf-(1-3)-b-D-Galp-(1-3)-b-L-Rhap2Ac-(1-2)-a-L-Rhap-(1-4)-b-D-GlcpA-(1-
/Variants 0/ is:
Ac-6)-
OR (exclusively)
Ac-5)-
The structure was elucidated in this paper NCBI PubMed ID:35483835 Publication DOI:10.1016/j.carbpol.2022.119414 Journal NLM ID:8307156 Publisher: Elsevier Correspondence: C. Zong <chengli.zonghainanu.edu.cn> Institutions: School of Pharmaceutical Sciences, College of Marine Science, Hainan University, Haikou 570228, China, The University of Sydney, NSW 2006, Australia, School of Pharmacy, Fudan University, Shanghai 201203, China
Around 100 Streptococcus pneumonia (Spn) serotypes have been discovered, 90% of the severe diseases in children are caused by 13 serotypes. With the success of pneumococcal bacterial polysaccharide conjugate vaccines (PCVs), the burden of pneumococcal disease has been significantly reduced. Serotype 31 is a non-vaccine serotype and has increased in prevalence. By using Nuclear Magnetic Resonance (NMR) as the primary tool, we report the revised serotype 31 polysaccharide (s-31-ps) structure as [→3)-β-D-Galf-(5/6-OAc)-(1→3)-β-D-Galp-(1→3)-β-L-Rhap-(2-OAc)-(1→2)-α-L-Rhap-(1→4)-β-D-GlcpA-(1→]n. Furthermore, the reductive amination-conjugate of serotype 31 polysaccharide and cross reacting material (CRM197) protein was prepared in organic solvent (N,N-dimethylformamide, DMF) instead of water. The reaction is faster, and the DMF conjugate elicited comparable immune responses with the aqueous conjugate. S-31-ps conjugate vaccine has the potential of being included in the next-generation PCV vaccines.
report error
Found 2 records.
Displayed records from 1 to 2
]
hainanu.edu.cn>